Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2002

View Archived Issues

New data on the efficacy and safety of valdecoxib

ABI-007 trial cleared to continue

Novel antifungal compound SF-2822 described by Meiji Seika researchers

Sankyo patents new antibacterial agents isolated from Streptomyces cultures

Antifungal cyclic peptides prepared and tested at Takara Shuzo

Cell Therapeutics presents new inhibitors of IL-12 and IL-4 signaling for asthma, diabetes, etc.

New DPP-IV inhibitors in early development at Boehringer Ingelheim

Toyama presents novel agents with neuroprotective and neurotrophic activity

Banyu describes novel compounds able to increase GLP-1 levels

Keryx extends international manufacturing and negotiating rights for KRX-101

CollaGenex signs copromotion deal with Novartis for Denavir

Saegis licenses preclinical compound from Lilly for cognitive impairment

British Biotech and Serono extend antiinflammatory research agreement

First of three pivotal phase III trials of AC-2993 in type 2 diabetes completes enrollment

Inhibition of p38 MAP kinase associated with significant antiinflammatory effects in CIA

Two Genzyme enzyme replacement therapies up for FDA panel review in January

Pascolizumab characterized preclinically prior to clinical studies

Octapeptide based on alpha-MSH combines both antiinflammatory and antiinfective properties

Further development of LY-333531 for diabetic neuropathy and vasculopathy warranted

Potent and gut-selective Ca2+ channel antagonist with potential in IBS

GSK and Biosynexus to develop and commercialize staphylococcal antibodies and vaccines

Phase III Provenge trial resumes enrollment

Second Allox phase I/II trial completed

Chiron announces discontinuation of various programs

Cerebril phase II IND cleared

COGNIShunt system receives European regulatory approval

Statin induces apoptosis in RA synoviocytes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...